Arcutis Biotherapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Arcutis Biotherapeutics has a total shareholder equity of $88.7M and total debt of $201.8M, which brings its debt-to-equity ratio to 227.6%. Its total assets and total liabilities are $341.4M and $252.7M respectively.
Key information
227.6%
Debt to equity ratio
US$201.80m
Debt
| Interest coverage ratio | n/a |
| Cash | US$271.86m |
| Equity | US$88.67m |
| Total liabilities | US$252.70m |
| Total assets | US$341.37m |
Recent financial health updates
Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?
May 02
Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?
Dec 18Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?
Aug 09Recent updates
Arcutis Biotherapeutics: Betting Big On Zoryve
May 01New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Apr 25Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues
Mar 03Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates
Mar 02Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up
Feb 28Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture
Jan 31Growth Investors: Industry Analysts Just Upgraded Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts By 21%
Oct 23Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher
Aug 13Earnings Release: Here's Why Analysts Cut Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Price Target To US$41.57
Aug 11Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?
May 02Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?
Dec 18Arcutis sees positive top-line results from roflumilast in scalp and body psoriasis
Sep 26Arcutis Biotherapeutics: A Name To Accumulate
Sep 18Arcutis acquires privately-held biotech Ducentis BioTherapeutics
Sep 07Arcutis launches plaque psoriasis therapy Zoryve in US
Aug 10Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?
Aug 09Financial Position Analysis
Short Term Liabilities: ARQT's short term assets ($330.4M) exceed its short term liabilities ($46.7M).
Long Term Liabilities: ARQT's short term assets ($330.4M) exceed its long term liabilities ($206.0M).
Debt to Equity History and Analysis
Debt Level: ARQT has more cash than its total debt.
Reducing Debt: ARQT's debt to equity ratio has increased from 0% to 227.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ARQT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ARQT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.